Transcend Therapeutics has officially completed its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. The deal marks an important step for Transcend as it continues developing rapid-acting treatments for neuropsychiatric disorders, particularly post-traumatic stress disorder (PTSD).
The acquisition was first announced on March 27, 2026. Following the completion of the transaction, Transcend Therapeutics now operates as a wholly owned subsidiary of Otsuka America Inc.
Since its launch in 2021, Transcend Therapeutics has focused on developing innovative treatments for patients living with neuropsychiatric conditions. The company’s primary goal has been to address treatment gaps for individuals who have not responded well to currently available therapies.
The acquisition is expected to provide Transcend with additional resources, broader global reach, and greater development capabilities as it advances its clinical programs.
Blake Mandell, Co-Founder and Chief Executive Officer of Transcend Therapeutics, stated that the company has made significant progress in a short period of time and believes joining Otsuka will help accelerate the development of new treatment options for patients with PTSD.
A major focus of the acquisition is TSND-201, Transcend’s lead investigational therapy currently being developed for PTSD and other central nervous system disorders.
TSND-201 is a rapid-acting neuroplastogen designed to support neural connectivity and brain function. The therapy has shown encouraging clinical progress over the last few years.
The program achieved several important milestones, including:
The ongoing Phase 3 study will further evaluate the safety and effectiveness of TSND-201 in patients living with PTSD.
What Makes TSND-201 Different?
TSND-201, also known as methylone, is being developed as a rapid-acting and durable treatment option for PTSD.
The investigational therapy primarily acts on monoamine transporters, which play a role in regulating mood and emotional responses. Unlike some other compounds in this category, TSND-201 does not activate 5-HT2A receptors and is not considered hallucinogenic.
Researchers believe this mechanism may offer a promising approach for addressing PTSD symptoms while maintaining a favorable treatment profile.
TSND-201 remains an investigational medicine and has not yet received regulatory approval.
Otsuka Expands Its Mental Health Portfolio
For Otsuka, the acquisition strengthens its commitment to developing innovative treatments for mental health conditions.
Tarek Rabah, President and CEO of Otsuka North America Pharmaceutical Business, noted that Transcend’s scientific approach aligns closely with Otsuka’s long-standing focus on addressing unmet needs in mental health care.
By combining Transcend’s research expertise with Otsuka’s global development capabilities, both companies aim to accelerate the delivery of new therapeutic options for patients affected by PTSD and other neuropsychiatric disorders.
Growing Need for Better PTSD Treatments
PTSD remains a significant public health challenge worldwide. Many patients continue to struggle despite currently available treatment options, creating demand for new therapies that can work more quickly and provide lasting benefits.
Rapid-acting treatments such as TSND-201 are attracting growing attention because they may offer a different approach compared to traditional psychiatric medications, which often require extended periods before showing clinical benefits.
The ongoing development of TSND-201 reflects a broader industry effort to bring innovative mental health therapies to patients who continue to face limited treatment choices.
About Transcend Therapeutics
Founded in 2021 and headquartered in New York City, Transcend Therapeutics is a clinical-stage neuroscience company focused on developing rapid-acting therapies for neuropsychiatric diseases. The company’s research is aimed at helping patients who have not achieved adequate results with existing psychiatric treatments.
About Otsuka
Otsuka Pharmaceutical is a global healthcare company focused on both physical and mental health. The company develops medicines, diagnostics, and health-related products designed to improve patient well-being and address unmet medical needs around the world.
Through its healthcare and nutraceutical businesses, Otsuka continues to invest in scientific innovation aimed at improving quality of life and expanding access to new treatment options.